AdaptHealth Sees FY23 Net Revenue Of $3.16B-$3.185B Versus Prior Guidance Of $3.16B-$3.2B Versus Consensus Of $3.17B; Sees Adjusted EBITDA Of $630M-$650M Versus Prior Guidance Of $650M-$680M
Portfolio Pulse from Benzinga Newsdesk
AdaptHealth has revised its FY23 net revenue guidance to $3.16B-$3.185B, slightly lower than its previous guidance of $3.16B-$3.2B and consensus of $3.17B. The company also lowered its adjusted EBITDA guidance to $630M-$650M from the previous $650M-$680M.
November 07, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AdaptHealth has lowered its FY23 net revenue and adjusted EBITDA guidance, which may negatively impact investor sentiment and the company's stock price in the short term.
AdaptHealth's lowered guidance for FY23 indicates potential challenges in the company's performance. This could lead to negative investor sentiment, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100